Folger Nolan Fleming Douglas Capital Management Inc. Sells 656 Shares of Abbott Laboratories $ABT

Folger Nolan Fleming Douglas Capital Management Inc. lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.7% during the 2nd quarter, Holdings Channel reports. The fund owned 95,796 shares of the healthcare product maker’s stock after selling 656 shares during the period. Abbott Laboratories comprises approximately 1.4% of Folger Nolan Fleming Douglas Capital Management Inc.’s holdings, making the stock its 18th largest position. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Abbott Laboratories were worth $13,029,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of ABT. Brighton Jones LLC lifted its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Abbott Laboratories by 17.0% during the 1st quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after purchasing an additional 5,590 shares during the last quarter. Zhang Financial LLC lifted its holdings in shares of Abbott Laboratories by 26.9% during the 1st quarter. Zhang Financial LLC now owns 5,933 shares of the healthcare product maker’s stock valued at $787,000 after purchasing an additional 1,259 shares during the last quarter. Baker Chad R lifted its holdings in shares of Abbott Laboratories by 0.4% during the 1st quarter. Baker Chad R now owns 107,680 shares of the healthcare product maker’s stock valued at $14,284,000 after purchasing an additional 455 shares during the last quarter. Finally, Relyea Zuckerberg Hanson LLC lifted its holdings in shares of Abbott Laboratories by 0.5% during the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 23,717 shares of the healthcare product maker’s stock valued at $3,146,000 after purchasing an additional 108 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $132.30 on Friday. The stock has a 50-day simple moving average of $132.54 and a two-hundred day simple moving average of $131.56. The firm has a market capitalization of $230.26 billion, a P/E ratio of 16.58, a PEG ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Wall Street Analyst Weigh In

ABT has been the subject of several analyst reports. Royal Bank Of Canada increased their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Wells Fargo & Company reduced their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research note on Friday, July 18th. Morgan Stanley raised their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Finally, Evercore ISI raised their target price on Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $146.17.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.